Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-012 season in Spain, among population targeted for vaccination
详细信息 查看全文
- 作者：Silvia Jiménez-Jorge (23) (24)
Salvador de Mateo (23) (24)
Concha Delgado-Sanz (23)
Francisco Pozo (25)
Inmaculada Casas (25)
Manuel Garcia-Cenoz (24) (26)
Jesús Castilla (24) (26)
Esteban Pérez (27)
Virtudes Gallardo (27)
Carolina Rodriguez (28)
Tomás Vega (28)
Carmen Qui?ones (29)
Eva Martínez (29)
Juana María Vanrell (30)
Jaume Giménez (30)
Daniel Castrillejo (31)
María del Carmen Serrano (32)
Julián Mauro Ramos (32)
Amparo Larrauri (23) (24) - 关键词：Influenza ; Vaccine effectiveness ; Case–control studies ; Sentinel networks ; Discordant strain ; Waning immunity
- 刊名：BMC Infectious Diseases
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：655 KB
- 参考文献：1. World Health Organization: Meeting of the strategic advisory group of experts on immunization, April 2012 - conclusions and recommendations. World Health Organization. 2012,87(21):201-16. http://www.who.int/wer/2012/wer8721.pdf.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA: Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. / Lancet Infect Dis 2011, 12:36-4. CrossRef
3. Mereckiene J, Cotter S, D’Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, Lopalco PL, Weber JT, Johansen K, Dematte L, Salmaso S, Stefanoff P, Greco D, Dorleans F, Polkowska A, O’Flanagan D: Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-009. / Euro Surveill 2010,15(44):1-0. mages/dynamic/EE/V15N44/art19700.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V15N44/art19700.pdf
4. Ministry of Health and Social Policy S: / Prevención de la gripe. Recomendaciones de vacunación antigripal [Influenza prevention. Recommendations for influenza vaccination]. Spain: Ministry of Health and Social Policy; 2011. msps.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/home.htm" class="a-plus-plus">http://www.msps.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/home.htm
5. Savulescu C, Valenciano M, de Mateo S, Larrauri A, the cycEVA Study Team: Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network–pilot case–control studies using different control groups, 2008-009 season, Spain. / Vaccine 2010,28(16):2903-907. CrossRef
6. Savulescu C, Jimenez-Jorge S, De Mateo S, Pozo F, Casas I, Perez-Brena P, Galmes A, Vanrell JM, Rodriguez C, Vega T, Martinez A, Torner N, Ramos JM, Serrano MC, Castilla J, Garcia CM, Altzibar JM, Arteagoitia JM, Qui?ones C, Perucha M, Larrauri A, on behalf of the Spanish Influenza Surveillance System: Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case controls studies, Spain, season 2009-010. / BMC Public Health 2011, 11:899-07. CrossRef
7. Jimenez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, Larrauri A: Effectiveness of the 2010-1 seasonal trivalent influenza vaccine in Spain: cycEVA study. / Vaccine 2012, 30:3595-602. CrossRef
8. Larrauri A, Savulescu C, Jimenez-Jorge S, Perez-Brena P, Pozo F, Casas I, Ledesma J, de Mateo S: Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008- trivalent vaccine against pandemic influenza in Spain. / Gac Sanit 2011,25(1):23-8. CrossRef
9. Valenciano M, Ciancio B, Moren A: First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA member states. / Euro Surveill 2008,13(43):1-. mages/dynamic/EE/V13N43/art19015.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V13N43/art19015.pdf
10. Kissling E, Valenciano M: Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case–control study, 2011/12. / Euro Surveill 2012,17(15):1-. mages/dynamic/EE/V17N15/art20146.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V17N15/art20146.pdf
11. Jimenez-Jorge S, de Mateo S, Pozo F, Casas I, Garcia CM, Castilla J, Gallardo V, Perez E, Vega T, Rodriguez C, Quinones C, Martinez E, Gimenez J, Vanrell J, Castrillejo D, Serrano M, Ramos J, Larrauri A: Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012. / Euro Surveill 2012,17(12):1-. mages/dynamic/EE/V17N12/art20129.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V17N12/art20129.pdf
12. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen J, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jimenez-Jorge S, Horvath J, Daviaud I, Guiomar R, Necula G, Bella A, Donnell O, Gluchowska M, Ciancio B, Nicoll A, Moren A: Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study. / Euro Surveill 2013.,18(5): mages/dynamic/EE/V18N05/art20390.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V18N05/art20390.pdf
13. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson C, Robertson C, Cottrell S, Smyth B, Zambon M, Moore C, Fleming D, Watson J: Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. / Euro Surveill 2013.,18(5): mages/dynamic/EE/V18N05/art20389.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V18N05/art20389.pdf
14. Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia CM, Guevara M, Moran J, Irisarri F, Arriazu M, Albeniz E, Ezpeleta C, Barricarte A: Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. / Euro Surveill 2013.,18(5): mages/dynamic/EE/V18N05/art20388.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V18N05/art20388.pdf
15. Skowronski DM, Tweed SA, De Serres G: Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? / J Infect Dis 2008,197(4):490-02. CrossRef
16. European Centre for Disease Prevention and Control: / Protocol for case–control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States. Technical document. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2009:1-7.
17. Rothman KJ, Greenland S, Lash TL, Rothman KJ, Greenland S, Lash TL: / editors.Modern epidemiology. 3rd edition. Philadelphia: Lippincott-Raven; 2008:128-7. Volume 9. Validity in epidemiologic studies
18. Jackson ML, Nelson JC: The test-negative design for estimating influenza vaccine effectiveness. / Vaccine 2013,31(17):2165-168. CrossRef
19. Foppa IM, Haber M, Ferdinands JM, Shay DK: The case test-negative design for studies of the effectiveness of seasonal influenza vaccine. / Vaccine 2013,31(30):3104-109. CrossRef
20. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, Kwindt TL, Chan T, Bastien N, Charest H, Li Y: Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-007. / J Infect Dis 2009,199(2):168-79. CrossRef
21. Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ, Miller E, Zambon M: Estimating influenza vaccine effectiveness using routinely collected laboratory data. / J Epidemiol Community Health 2010,64(12):1062-067. CrossRef
22. Kelly H, Valenciano M: Estimating the effect of influenza vaccines. / Lancet Infect Dis 2012,12(1):5-. m/S1473309911702894/1-s2.0-S1473309911702894-main.pdf?_tid=3b3875ecef41e3c86ee2403d8cfab8b2&acdnat=1343039760_9612548832981a739951cf59b3638fd9" class="a-plus-plus">http://ac.els-cdn.com/S1473309911702894/1-s2.0-S1473309911702894-main.pdf?_ tid=3b3875ecef41e3c86ee2403d8cfab8b 2&acdnat=1343039760_96125488329 81a739951cf59b3638fd9 CrossRef
23. Valenciano M, Kissling E, Ciancio BC, Moren A: Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. / Vaccine 2010,28(46):7381-388. m/science/article/pii/S0264410X10013186" class="a-plus-plus">http://www.sciencedirect.com/science/article/pii/S0264410X10013186 CrossRef
24. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK: Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-005 season to the 2006-007 season. / J Infect Dis 2009,199(2):159-7. CrossRef
25. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, Sebastian R, Chong M, Tam T, De Serres G: Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-006 season of dual A and B vaccine mismatch in Canada. / Vaccine 2007,25(15):2842-851. m/science/article/pii/S0264410X06011054" class="a-plus-plus">http://www.sciencedirect.com/science/article/pii/S0264410X06011054 CrossRef
26. Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I: Estimation of influenza vaccine effectiveness from routine surveillance data. / PLoS ONE 2009,4(3):e5079. CrossRef
27. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, Orenstein WA: Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. / Int J Epidemiol 2007,36(3):623-31. http://ije.oxfordjournals.org/content/36/3/623.full.pdf+html m021" target="_blank" title="It opens in new window">CrossRef
28. Puig-Barbera J: 2010-011 influenza seasonal vaccine, preliminary mid-season effectiveness estimates: reason for concern, confounding or are we following the right track? / Euro Surveill 2011.,16(11): mages/dynamic/EE/V16N11/art19821.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V16N11/art19821.pdf
29. World Health Organization: Review of the 2011-012 winter influenza season, northern hemisphere. / Weekly epidemiological record 2012,24(87):233-40. http://www.who.int/wer/2012/wer8724.pdf
30. Centro Nacional de Epidemiología.Instituto de Salud Carlos II: / Informes anuales de gripe. Vigilancia de la Gripe en Espa?a. Sistema centinela. Centro Nacional de Epidemiología.Instituto de Salud Carlos III; 2012. medades/gripe.shtml" class="a-plus-plus">http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/gripe.shtml. Accessed: 10 May 2013
31. European Centre for Disease Control and Prevention (ECDC): / European Centre for Disease Control and Prevention (ECDC), Technical document. Influenza virus characterisation - Summary Europe. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2012:1.
32. Fielding JE, Grant KA, Tran T, Kelly HA: Moderate influenza vaccine effectiveness in Victoria, Australia, 2011. / Euro Surveill 2012,17(11):1-. mages/dynamic/EE/V17N11/art20115.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V17N11/art20115.pdf
33. Fielding JE, Grant KA, Papadakis G, Kelly HA: Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-008. / BMC Infect Dis 2011, 11:170-78. CrossRef
34. Carrat F, Flahault A: Influenza vaccine: the challenge of antigenic drift. / Vaccine 2007,25(39-0):6852-862. CrossRef
35. Centers for Disease Control and Prevention: Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-8 influenza season. / MMWR Morb Mortal Wkly Rep 2008,57(15):393-98. mmwr/preview/mmwrhtml/mm5715a1.htm" class="a-plus-plus">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5715a1.htm
36. World Health Organization: / Recommended composition of influenza virus vaccines for use in the 2012-013 northern hemisphere influenza season [Internet]. World Health Organization; 2012:1-6. mmendations/201202_recommendation.pdf" class="a-plus-plus">http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf
37. Gross PA, Russo C, Teplitzky M, Dran S, Cataruozolo P, Munk G: Time to peak serum antibody response to influenza vaccine in the elderly. / Clin Diagn Lab Immunol 1996,3(3):361-62.
38. Brydak LB, Machala M, Mysliwska J, Mysliwski A, Trzonkowski P: Immune response to influenza vaccination in an elderly population. / J Clin Immunol 2003,23(3):214-22. CrossRef
39. Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, Sambhara S: Immunosenescence and challenges of vaccination against influenza in the aging population. / Aging Dis 2012,3(1):68-0. m.nih.gov/pmc/articles/PMC3320806/pdf/ad-3-1-68.pdf" class="a-plus-plus">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320806/pdf/ad-3--68.pdf
40. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O’Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jimenez-Jorge S, Savulescu C, Ciancio B, Moren A: I-MOVE multi-centre case control study 2010-1: overall and stratified estimates of influenza vaccine effectiveness in Europe. / PLoS ONE 2011,6(11):e27622. CrossRef
41. Beyer WE, Palache AM, Baljet M, Masurel N: Antibody induction by influenza vaccines in the elderly: a review of the literature. / Vaccine 1989,7(5):385-94. CrossRef
42. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA: Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. / Vaccine 1994,12(13):1185-189. CrossRef
43. Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Thomas D, Sebastianpillai P, Ellis J, Carman W, Wreghitt T, Zambon M, Watson J: Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. / Euro Surveill 2011,16(6):1-. mages/dynamic/EE/V16N06/art19791.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V16N06/art19791.pdf
44. Castilla J, Moran J, Martinez-Artola V, Reina G, Martinez-Baz I, Garcia CM, Alvarez N, Irisarri F, Arriazu M, Elia F, Salcedo E: Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. / Euro Surveill 2011,16(7):1-. mages/dynamic/EE/V16N07/art19799.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V16N07/art19799.pdf
45. Savulescu C, Jimenez-Jorge S, de Mateo S, Ledesma J, Pozo F, Casas I, Larrauri A: Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case–control study. / Euro Surveill 2011,16(11):1-. mages/dynamic/EE/V16N11/art19820.pdf" class="a-plus-plus">http://www.eurosurveillance.org/images/dynamic/EE/V16N11/art19820.pdf
46. Nicoll A, Sprenger M: Low effectiveness undermines promotion of seasonal influenza vaccine. / Lancet Infect Dis 2013,13(1):7-. CrossRef
47. The pre-publication history for this paper can be accessed here:medcentral.com/1471-2334/13/441/prepub" class="a-plus-plus">http://www.biomedcentral.com/1471-2334/13/441/prepub - 作者单位：Silvia Jiménez-Jorge (23) (24)
Salvador de Mateo (23) (24)
Concha Delgado-Sanz (23)
Francisco Pozo (25)
Inmaculada Casas (25)
Manuel Garcia-Cenoz (24) (26)
Jesús Castilla (24) (26)
Esteban Pérez (27)
Virtudes Gallardo (27)
Carolina Rodriguez (28)
Tomás Vega (28)
Carmen Qui?ones (29)
Eva Martínez (29)
Juana María Vanrell (30)
Jaume Giménez (30)
Daniel Castrillejo (31)
María del Carmen Serrano (32)
Julián Mauro Ramos (32)
Amparo Larrauri (23) (24)
23. National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no. 5, Madrid, 28029, Spain
24. Ciber Epidemiología y Salud Pública (CIBERESP), Ministry of Science and Innovation, Institute of Health Carlos III, Madrid, Spain
25. National Centre for Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Institute of Health Carlos III, Majadahonda, Madrid, 28220, Spain
26. Instituto de Salud Pública de Navarra, Navarra, Spain
27. Servicio de Epidemiología y Salud Laboral. Secretaría General de Salud Pública y Participación. Consejería de Salud de Andalucía, Consejería, Spain
28. Dirección General de Salud Pública, Consejería de Sanidad de Castilla y León, kragujevac, Spain
29. Servicio de Epidemiología, Subdirección de Salud Pública de La Rioja, La Rioja, Spain
30. Servicio de Epidemiología, Dirección General de Salut Pública, Baleares, Spain
31. Servicio de Epidemiología. Dirección General de Sanidad y Consumo, Consejería de Bienestar Social y Sanidad, Ciudad Autónoma de Melilla, Spain
32. Dirección General de Salud Pública, Servicio Extreme?o de Salud, Junta de Extremadura, Spain - ISSN：1471-2334
文摘
Background In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using the observational study cycEVA conducted in the frame of the existing Spanish Influenza Sentinel Surveillance System. The objective of the study was to estimate influenza vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza-like illness (ILI) among the target groups for vaccination in Spain in the 2011-012 season. We also studied influenza VE in the early (weeks 52/2011-7/2012) and late (weeks 8-14/2012) phases of the epidemic and according to time since vaccination. Methods Medically attended patients with ILI were systematically swabbed to collect information on exposure, laboratory outcome and confounding factors. Patients belonging to target groups for vaccination and who were swabbed <8?days after symptom onset were included. Cases tested positive for influenza and controls tested negative for any influenza virus. To examine the effect of a late season, analyses were performed according to the phase of the season and according to the time between vaccination and symptoms onset. Results The overall adjusted influenza VE against A(H3N2) was 45% (95% CI, 0-9). The estimated influenza VE was 52% (95% CI, -3 to 78), 40% (95% CI, -40 to 74) and 22% (95% CI, -135 to 74) at 3.5?months, 3.5-4?months, and >4?months, respectively, since vaccination. A decrease in VE with time since vaccination was only observed in individuals aged?≥-5?years. Regarding the phase of the season, decreasing point estimates were only observed in the early phase, whereas very low or null estimates were obtained in the late phase for the shortest time interval. Conclusions The 2011-012 influenza vaccine showed a low-to-moderate protective effect against medically attended, laboratory-confirmed influenza in the target groups for vaccination, in a late season and with a limited match between the vaccine and circulating strains. The suggested decrease in influenza VE with time since vaccination was mostly observed in the elderly population. The decreasing protective effect of the vaccine in the late part of the season could be related to waning vaccine protection because no viral changes were identified throughout the season.